Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

This large population-based case-control study evaluated whether angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with increased risk of Covid-19. Researchers analyzed data from over 6,200 confirmed SARS-CoV-2 cases and more than 30,000 matched controls in Lombardy, Italy. Although users of ACE inhibitors and ARBs were more likely to have Covid-19 compared to controls, these patients also had a higher prevalence of underlying cardiovascular conditions. After adjusting for comorbidities and concurrent medications, no independent association was found between the use of ACE inhibitors or ARBs and either the incidence or severity of Covid-19. The findings support continued use of these medications for approved indications during the pandemic.

This large population-based case-control study evaluated whether angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with increased risk of Covid-19. Researchers analyzed data from over 6,200 confirmed SARS-CoV-2 cases and more than 30,000 matched controls in Lombardy, Italy. Although users of ACE inhibitors and ARBs were more likely to have Covid-19 compared to controls, these patients also had a higher prevalence of underlying cardiovascular conditions. After adjusting for comorbidities and concurrent medications, no independent association was found between the use of ACE inhibitors or ARBs and either the incidence or severity of Covid-19. The findings support continued use of these medications for approved indications during the pandemic.